On January 23, doctors, scientists and researchers will gather for a symposium about Microsatellite Instability (MSI) at Duke University. During the one-day event, scientists from Duke University and The Ohio State University will share insight into their research on biomarkers, MSI status and GI cancer, Lynch Syndrome, and MSI and DNA mismatch repair deficiency (dMMR).
Biomarkers in Clinical Trial Design: Implementation and Analysis.
Presented by Andrew Nixon, PhD, MBA; Duke University
Dr. Nixon is an Associate Professor of Medicine, a member of the Duke Cancer Institute, and the Director of the Phase I Biomarker Laboratory. Dr. Nixon will act as the moderator for the afternoon round table discussion.
Clinical Diagnostic testing for Microsatellite Instability (MSI) and DNA Mismatch Repair (MMR) deficiency status at Duke Health.
Dr. Sebastian is a Professor of Pathology and Dr. Parrilla is an Assistant Professor of Pathology and an Assistant Professor of Surgery.
Clinical Testing and Implication of MSI Testing in GI Cancers
Presented by Gerard C. Blobe MD, PhD; Duke University
Dr. Blobe is a Professor of Medicine, Professor of Pharmacology and Cancer Biology, an Associate of the Duke Initiative for Science and Society, and a Member of the Duke Cancer Institute.
Lynch syndrome and screening
Presented by Heather Hampel, MS, LGC; The Ohio State University
Ms. Hempel is a Licensed Genetic Counselor, an Associate Director, Division of Human Genetics; Associate Director, Biospecimen Research; and a Professor of Clinical Internal Medicine at The Ohio State University Comprehensive Cancer Center.
Assessing genomic instability using microsatellite loci: A historical review and future perspectives
Presented by Heather Tomlinson, PhD; Promega Corporation
Dr. Tomlinson is the Director of Clinical Diagnostics for Promega Corporation.
Would you like to attend?
If you want to register you can use this link: Register
This symposium is sponsored by Promega Corporation.